| Literature DB >> 31487267 |
Sanda Win1, Robert Wm Min1, Christopher Q Chen1, Jun Zhang2, Yibu Chen3, Meng Li3, Ayako Suzuki4, Manal F Abdelmalek4, Ying Wang4, Mariam Aghajan5, Filbert Wm Aung1, Anna Mae Diehl4, Roger J Davis6, Tin A Than1, Neil Kaplowitz1.
Abstract
SH3 domain-binding protein that preferentially associates with Btk (SAB) is an outer-membrane docking protein for JNK-mediated impairment of mitochondrial function. Deletion of Sab in hepatocytes inhibits sustained JNK activation and cell death. The current study demonstrates that an increase in SAB expression enhanced the severity of acetaminophen-induced (APAP-induced) liver injury. Female mice were resistant to liver injury and exhibited markedly decreased hepatic SAB protein expression compared with male mice. The mechanism of SAB repression involved a pathway from ERα to p53 expression that induced miR34a-5p. miR34a-5p targeted the Sab mRNA coding region, thereby repressing SAB expression. Fulvestrant or p53 knockdown decreased miR34a-5p and increased SAB expression in female mice, leading to increased injury from APAP and TNF/galactosamine. In contrast, an ERα agonist increased p53 and miR34a-5p, which decreased SAB expression and hepatotoxicity in male mice. Hepatocyte-specific deletion of miR34a also increased the severity of liver injury in female mice, which was prevented by GalNAc-ASO knockdown of Sab. Similar to mice, premenopausal women expressed elevated levels of hepatic p53 and low levels of SAB, whereas age-matched men expressed low levels of p53 and high levels of SAB, but there was no difference in SAB expression between the sexes in the postmenopausal stage. In conclusion, SAB expression levels determined the severity of JNK-dependent liver injury. Female mice expressed low levels of hepatic SAB protein because of the ERα/p53/miR34a pathway, which repressed SAB expression and accounted for the resistance to liver injury seen in these females.Entities:
Keywords: Apoptosis; Hepatology; P53; Sex hormones
Mesh:
Substances:
Year: 2019 PMID: 31487267 PMCID: PMC6877311 DOI: 10.1172/JCI128289
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808